Tandem Diabetes Care (TNDM) Non-Current Deffered Revenue (2013 - 2026)

Tandem Diabetes Care's Non-Current Deffered Revenue history runs 12 years deep, the most recent figure standing at $8.0 million for Q1 2026.

• Quarterly Non-Current Deffered Revenue fell 18.91% year-over-year to $8.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.0 million (down 18.91% YoY) and the FY2025 annual result came in at $8.5 million, down 18.95% from the prior year.
• Non-Current Deffered Revenue was $8.0 million for Q1 2026 at Tandem Diabetes Care, down from $8.5 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $19.1 million in Q3 2022 and bottomed at $8.0 million in Q1 2026.
• A 5-year average of $13.0 million and a median of $12.3 million in 2024 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2022 — Non-Current Deffered Revenue retreated 0.39% — and 2023, when it retreated 26.4%.
• Tandem Diabetes Care's Non-Current Deffered Revenue stood at $16.9 million in 2022, then slipped by 21.0% to $13.3 million in 2023, then retreated by 21.57% to $10.5 million in 2024, then dropped by 18.95% to $8.5 million in 2025, then slipped by 5.66% to $8.0 million in 2026.
• Business Quant data shows TNDM's Non-Current Deffered Revenue at $8.0 million in Q1 2026, $8.5 million in Q4 2025, and $8.8 million in Q3 2025.